Navigation Links
Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344
Date:5/29/2012

SAN DIEGO, May 29, 2012 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that the first cohort of patients has been dosed in a Phase I clinical trial of ME-344, the Company's lead mitochondrial inhibitor drug candidate, in patients with refractory solid tumors. The dose escalation trial is expected to enroll up to 24 patients in up to five cohorts with final safety and pharmacokinetic data expected in the first half of 2013.

"We are very pleased to see the excitement surrounding our initial clinical trial of ME-344, with the first cohort of patients now well underway just a month after our Investigational New Drug application was approved by the FDA," said Robert D. Mass, MD, Chief Medical Officer of Marshall Edwards. "ME-344 is a novel compound that showed compelling anti-tumor activity in pre-clinical studies. Now we look forward to gathering valuable clinical data in the months ahead, all of which will help to optimize the design of our Phase II efficacy studies."

The Phase I clinical trial is evaluating the safety and tolerability of intravenous ME-344 in escalating dose cohorts of 1.2 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg. In addition, the trial is designed to characterize the pharmacokinetic profile of ME-344 and describe any preliminary clinical anti-tumor activity observed. Patients in the trial are administered intravenous infusions of ME-344 once weekly for three weeks and, after safety assessment, may continue weekly dosing if a clinical benefit is determined.

The open-label trial is being conducted in collaboration with the Sarah Cannon Research Institute at three sites: Florida Cancer Specialists in Sarasota, University of Oklahoma in Oklahoma City and Tennessee Oncology in Nashville. Additional information
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering
2. Marshall Edwards Receives $4 Million Subscription From Novogen In Rights Offering
3. Marshall Edwards Submits Investigational New Drug Application for Oncology Drug Candidate ME-344
4. Marshall Edwards CEO to Present at Roth Capital Partners Growth Stock Conference
5. Marshall Edwards Announces Rights Offering to Stockholders
6. Marshall Edwards Adds $2 Million in Private Placement
7. Marshall Edwards Announces $2 Million Private Placement
8. Marshall Edwards Announces First Patient Dosed in Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
9. Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
10. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
11. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  The board of ... a leading provider of clinical trial imaging solutions, today ... named chief financial officer, effective immediately.  Mr. Groff has ... August 2013.  He joined VirtualScopics in January 2006 as ... February 2013. "When the board of VirtualScopics ...
(Date:8/21/2014)... SAN JOSE, Calif. , Aug. 21, 2014 /PRNewswire/ ... a medical device company that pioneered the use of ... surgical (MIS) device indicated for fusion of the sacroiliac ... ) published an update to its Lumbar Fusion ... MIS SI joint fusion procedure.  The policy states that ...
(Date:8/20/2014)... , Aug. 20, 2014  The National ... the latest results achieved by the real-time, pseudoephedrine ... the National Precursor Log Exchange (NPLEx), automatically blocks ... track down meth offenders and make arrests. Data ... Kentucky blocked the sale of ...
Breaking Medicine Technology:VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3Kentucky's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... 22, 2011 GeNO LLC ( www.genollc.com ), ... announced commencement of  the PHiano Study: A Phase ... Hypertension in patients with Pulmonary Arterial Hypertension (PAH) ... (PH-IPF) using Inhaled NITROSYL™ nitric oxide (NO).  The ...
... March 22, 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ...  J. Michael Pearson, currently Valeant,s Chief Executive Officer (CEO), as ... who remains on the Valeant Board as an independent Board ... role as CEO and has agreed to extend his contract ...
Cached Medicine Technology:GeNO LLC Initiates Study of Inhaled NITROSYL™ Nitric Oxide in Idiopathic Pulmonary Fibrosis (PH-IPF) and Pulmonary Arterial Hypertension (PAH) Patients 2GeNO LLC Initiates Study of Inhaled NITROSYL™ Nitric Oxide in Idiopathic Pulmonary Fibrosis (PH-IPF) and Pulmonary Arterial Hypertension (PAH) Patients 3
(Date:8/22/2014)... Reacting to naysayers who are being skeptical about the ... PRP therapy LA specialist has firmly stated that the ... practical well researched science and nothing to do with ... medical breakthrough technology which focuses on healing and repair ... , The Managing Director of one of the top ...
(Date:8/22/2014)... 2014 Teen substance abuse has long ... Unfortunately, most young adults never receive the professional treatment ... community, the new Troubled Teens Columbus helpline was established ... overcome their drug and alcohol dependencies . ... and their parents can speak directly to a representative ...
(Date:8/22/2014)... Aid in Recovery, a full service ... regarding a recent bill introduced in the ... current legislator and retired police general. In House Bill ... offenders, rather than imprisonment. Aid in Recovery points to ... for the drug addiction epidemic. , The bill, introduced ...
(Date:8/21/2014)... August 22, 2014 Yoga Darshana Center, ... Island region, proudly announces the launch of their newest ... the West Babylon-based yoga studio’s new teacher training program, ... become teachers realize their dreams. , Since 2001, Yoga ... living in the surrounding area a place to learn ...
(Date:8/21/2014)... UWDress.com, a well-known wedding dress manufacturer, has added a new ... store. In addition to this, all these beautiful gowns are ... at the moment. The special offer will last from this ... workers have updated its online category with these affordable, elegant ... is a one stop place where worldwide people can buy ...
Breaking Medicine News(10 mins):Health News:MetroMD With The Help Of PRP Therapy Helps People Fight Hip Injuries 2Health News:New Helpline in Columbus Assists Troubled Teen Find Youth Rehab 2Health News:Proposed Legislature in the Philippines Highlights the Need for Rehabilitation, Not Incarceration, for Drug Users, Says Aid in Recovery 2Health News:Proposed Legislature in the Philippines Highlights the Need for Rehabilitation, Not Incarceration, for Drug Users, Says Aid in Recovery 3Health News:Yoga Darshana Center Announces Launch of New Website LongIslandYogaTeacherTraining.com 2Health News:Beautiful Peacock Party Dresses for 2014 Offered by UWDress.com at the Moment 2
... China, April 9, 2008 /Xinhua-PRNewswire-FirstCall/ -- China ... or "the Company") (OTC Bulletin,Board: CSKI), a ... pharmaceuticals for external use in the People,s ... announced that it has,closed its acquisition of ...
... 9, 2008 Eurosport Active World, Corp.,(Pink Sheets: ... and,Eagle International Holdings Group, Inc. have completed a ... common stock,trades on the "Pink Sheets" under the ... merged. Subsequent to a 1000:1 reverse stock,split, the ...
... men shouldn,t presume relationship is wanted based on appearance ... -- Young adults can discern another person,s attitude toward ... face, according to a British study of 700 heterosexual ... men generally prefer women who they believe are open ...
... to Grant Call Option to Subscribe for 19.99% New Shares of ... ... China Medical Services Business, HONG KONG, April 9, 2008 /Xinhua-PRNewswire/ ... service groups,in Hong Kong, ("Town Health" or the "Group"; SEHK: 8138) ...
... Create Leading, Full-Service Global Graphic ... Communication Services Organization, NEW ... New York-based private equity firm that invests in middle-market,specialty ... has completed its acquisition of Diversified Global,Graphics Group ("DG3"). ...
... LAKE CITY, April 9, 2008 UCN, Inc.,(Nasdaq: ... center,solutions announced today that a premiere national non-profit,patient-advocacy ... to use the UCN inContact(R) solution across six ... Advocate Foundation performed a thorough search and determined,that ...
Cached Medicine News:Health News:China Sky One Medical, Inc. Closes Acquisition of Heilongjiang Tianlong Pharmaceutical, Inc. 2Health News:China Sky One Medical, Inc. Closes Acquisition of Heilongjiang Tianlong Pharmaceutical, Inc. 3Health News:Faces May Provide Clues to Sexual Attitudes 2Health News:Town Health and Ping An Insurance (Group) Company of China, Ltd. Join Forces to Develop and Manage Clinic Chain in Pearl River Delta Area 2Health News:Town Health and Ping An Insurance (Group) Company of China, Ltd. Join Forces to Develop and Manage Clinic Chain in Pearl River Delta Area 3Health News:Town Health and Ping An Insurance (Group) Company of China, Ltd. Join Forces to Develop and Manage Clinic Chain in Pearl River Delta Area 4Health News:Town Health and Ping An Insurance (Group) Company of China, Ltd. Join Forces to Develop and Manage Clinic Chain in Pearl River Delta Area 5Health News:Town Health and Ping An Insurance (Group) Company of China, Ltd. Join Forces to Develop and Manage Clinic Chain in Pearl River Delta Area 6Health News:Town Health and Ping An Insurance (Group) Company of China, Ltd. Join Forces to Develop and Manage Clinic Chain in Pearl River Delta Area 7Health News:Arsenal Capital Partners Invests in DG3 2Health News:Arsenal Capital Partners Invests in DG3 3Health News:Nation's Premiere Patient Advocate Organization Commits to UCN inContact(R) for Entire Group 2Health News:Nation's Premiere Patient Advocate Organization Commits to UCN inContact(R) for Entire Group 3
... selecting an oxygen conserver, it's important to have ... Now allied, a name synonymous with innovative excellence, ... Liberty™, two totally automatic and value packed conservers., ... Liberty can be used 8 hours a day ...
Proven and Efficient Stand-Alone Device. Offers a choice between alternate breath and every breath delivery. This model provides every breath delivery....
Lightweight Pneumatic Conserver., ,NOTE: All models passed the ASTM PS 127-00 regulator ignition safety test....
... ,Offers an average 5:1 increase in usage ... use of a standard cannula. , ,The ... offers ambulatory oxygen patients a superior alternative to ... 2-year warranty. , ...
Medicine Products: